Global Targeted Drug Delivery Market Size Report Segmented by Technology (Nanoparticles, Liposomes, ADCs), Route of Administration (Injectable, Oral, Pulmonary, Transdermal, Nasal), Application (Oncology, CVDs, Neurological Disorders), Regional Forecast to 2031
The global targeted drug delivery market size is set to grow at a CAGR of 12% over the next 5 years. Rising prevalence of cancer and chronic diseases; growth of precision medicine; advancements in nanotechnology; expansion of biologics, gene therapies, and RNA therapeutics; and increasing success of antibody-drug conjugates (ADCs) are some key factors driving the growth of the targeted drug delivery market. To learn more about the research report, download a sample report.
Targeted drug delivery is a form of therapy that allows medication to be injected directly into affected cells/tissues/organs/disease sites while limiting exposure of normal surrounding tissues to the drug by using specialized carriers. These carriers include nanoparticles, liposomes, antibody-drug conjugates (ADCs), lipid nanoparticles (LNP), polymers, and exosomes, among others, all of which are designed to help deliver the medication exactly where it is needed, in the desired amount, at the right time, and with minimal systemic exposure. By concentrating medication at the desired location, targeted delivery helps to decrease adverse effects and improve overall efficacy of treatment and enables lower dosing requirements. Targeted drug delivery has long been used in the field of oncology and is now being investigated and applied in cardiovascular, neurological, autoimmune, infectious disease, gene therapy, and RNA therapies among others.
Growth of precision medicine to propel market demand
Targeted drug delivery is being driven by the increase in the use of precision medicine, where healthcare providers are looking for treatment options that match the individual characteristics of patients, such as their genetics and other biological characteristics as well as their individual diseases. Precision medicine uses many new technologies, including nanoparticles, liposomes, lipid nanoparticles (LNPs), antibody-drug conjugates (ADCs), and exosomes as carriers for the delivery of therapeutics and therefore need specialized delivery systems that are able to deliver a drug to only the desired cell or molecule.
Therefore, the increasing number of advanced delivery systems are leading to enhanced use of these technologies and have resulted in increased use of biomarker-driven therapies in cancers, rare diseases and genetic disorders, creating further demand for sophisticated targeted delivery technologies. In addition, the growing interest in the development of gene therapies, RNA therapies, and personalized biologics is creating ongoing demand for delivery systems to safely and effectively deliver unique complex molecules to a specific tissue for continued market growth.
To learn more about this report, download the PDF brochure
Â
Expansion of biologics, gene therapies, and RNA therapeutics are fueling the demand for targeted drug delivery systems
Biologics, gene therapies, and RNA therapeutic products are increasing demand for the targeted drug delivery system due to their need for specialized drug delivery systems to achieve required efficacy and safety. Biologic drugs like mRNA, siRNA, and gene editing are large, fragile molecules and can become inactivated rapidly in humans and may not reach their intended site of action. Due of this, pharmaceutical companies and biotechnologies have turned to targeted drug delivery systems like LNPs, liposomes, polymer carriers, ADCs, and exosome-based systems, among others.
These systems can protect a therapeutic payload, improve cell uptake, provide tissue targeting and decrease off-target effects. The success of delivering effective mRNA vaccines and gene therapies, plus developing RNA-based medicines has created a focus for continued improved delivery systems. The large number of personalized biologics and nucleic acid therapeutic development pipelines is creating a subsequent demand for new types of targeted drug delivery systems and greater investment and research into this market as well as commercialization of these types of therapies.
To learn more about this report, download the PDF brochure
Â
Technology Segment Outlook
Nanoparticles accounted for the largest share of this market in 2025. Its widespread use in treating various diseases such as cancer, infections, cardiovascular disorders, and genetic conditions has made it an ideal technology for many approved and pipeline therapies since it improves solubility; increase availability; protect drugs through the entire therapeutic process before delivery; and allow for controlled, localized delivery of medicines. Moreover, lipid nanoparticles have rapidly become the method of choice for mRNA vaccines and RNA-based therapies, thereby reinforcing nanoparticle technology's leading position in the market.
While nanoparticles currently represent the largest market segment, antibody-drug conjugates (ADCs) are projected to have the highest rate of growth in the coming years due to their dual benefits of targeted specificity through monoclonal antibodies and the cytotoxic activity of chemotherapy agents. Factors leading to the increased acceptance of ADCs include a rapidly increasing base of regulatory approvals, excellent clinical results in oncology, an expanding pipeline of research and development activity surrounding ADCs, and substantial investment by pharmaceutical companies into ADC development. As personalized medicine continues to evolve, ADCs are likely to experience the strongest growth among all of the other types of targeted drug delivery technologies assessed herein.
Regional Outlook: Growing investments in biologics and vaccine manufacturing are supporting North American market expansion
North America leads the global market as it is home to the largest pharmaceutical and biopharmaceutical companies, has a well-established system for investing in drug discovery and nanomedicine research, has high-quality healthcare infrastructure, and provides good support for both precision medicine and biologics. The region has also developed a solid ecosystem for conducting clinical trials and has many government agencies providing favorable regulatory assistance for innovative therapies. At the same time, the Asia-Pacific region continues to grow rapidly due to increase in overall healthcare spending, rise in the number of people suffering from chronic disease, increase in the capability of manufacturers to produce biopharmaceuticals, increase in the amount of money being spent on biotechnology research, and increase in the ability of countries such as China, India, Japan, and South Korea to access cutting-edge therapeutic products.
Competitive Landscape Analysis
The global targeted drug delivery market is marked by the presence of established and emerging market players such as-
- AbbVie Inc. (US)
- AstraZeneca (UK)
- Pfizer Inc. (US)
- Baxter (US)
- Boston Scientific Corporation (US)
- Becton, Dickinson and Company (BD) (US)
- Sanofi (France)
- Hoffmann-La Roche Ltd (Switzerland)
- Johnson & Johnson (US)
- Arrowhead Pharmaceuticals, Inc. (US)
Get a sample report for competitive landscape analysis
Â
Growth strategies adopted by players to establish their foothold in the targeted drug delivery market
Players operating in this market are adopting various growth strategies such as new product launches and approvals; acquisitions; expansions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,
- In November 2025, Curapath and Cristal Therapeutics entered a co-exclusive licensing partnership to integrate the CliCr bioconjugation platform into polymer and lipid nanoparticle-based drug delivery systems. The collaboration enhances targeted delivery of nucleic acid therapeutics by enabling precise and scalable biomolecule conjugation, supporting improved delivery to extrahepatic tissues such as the lungs, brain, and T cells for next-generation therapies
- In June 2025, Continuity Biosciences acquired Focal Medical to advance targeted drug delivery for pancreatic cancer and other solid tumors through Focal’s proprietary iontophoresis-based site-specific chemotherapy platform. The acquisition strengthens Continuity’s targeted therapeutics portfolio by adding FDA-cleared localized drug delivery technology, intellectual property, scientific expertise, and R&D capabilities aimed at improving drug concentration at tumor sites while reducing systemic toxicity
- In September 2024, Evonik launched EUDRACAP colon, the first ready-to-fill functional capsule designed for targeted delivery of sensitive therapeutics, including biologics, RNA, and live biotherapeutics, to the ileo-colonic region. The innovation expands Evonik’s oral drug delivery portfolio, simplifies formulation development, and supports the growing demand for advanced targeted oral drug delivery systems
Report Scope
|
Report Metric |
Details |
|
Base Year Considered |
2025 |
|
Historical Data |
2024 – 2025 |
|
Forecast Period |
2026 – 2031 |
|
Growth Rate |
12% |
|
Segment Scope |
Technology, Route of Administration, Application, and End User |
|
Regional Scope |
|
|
Market Drivers |
|
|
Attractive Opportunities |
|
|
Key Companies Mapped |
AbbVie Inc. (US); AstraZeneca (UK); Pfizer Inc. (US); Baxter (US); Boston Scientific Corporation (US); Becton, Dickinson and Company (BD) (US); Sanofi (France); F. Hoffmann-La Roche Ltd (Switzerland); Johnson & Johnson (US); and Arrowhead Pharmaceuticals, Inc. (US); among others |
|
Report Highlights |
Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Â
Global Targeted Drug Delivery Market Segmentation
This report by Medi-Tech Insights provides the size of the global targeted drug delivery market at the regional and country-level from 2024 to 2031. The report further segments the market by technology, route of administration, application, and end user.
Market Size & Forecast (2024-2031), By Technology, USD Billion
- Nanoparticles
- Liposomes
- Antibody-drug Conjugates (ADCs)
- Microspheres and Microcapsules
- Other Technologies
Market Size & Forecast (2024-2031), By Route of Administration, USD Billion
- Injectable
- Oral
- Pulmonary
- Transdermal
- Nasal
- Other Delivery Routes
Market Size & Forecast (2024-2031), By Application, USD Billion
- Oncology
- Cardiovascular Diseases (CVDs)
- Neurological Disorders
- Infectious Diseases
- Respiratory Diseases
- Metabolic Disorders
- Other Applications
Market Size & Forecast (2024-2031), By End User, USD Billion
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutes
- Hospitals and Clinics
- Other End Users
Market Size & Forecast (2024-2031), By Region, USD Billion
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
- Introduction
- Introduction​
- Market Scope​
- Market Definition​
- Segments Covered​
- Regional Segmentation​
- Research Timeframe​
- Currency Considered​
- Study Limitations​
- Stakeholders​
- List of Abbreviations​
- Key Conferences and Events (2026-2027)​
- Research Methodology​
- Secondary Research​
- Primary Research​
- Market Estimation​
- Bottom-Up Approach​
- Top-Down Approach​
- Market Forecasting​
- Executive Summary
- Targeted Drug Delivery Market Snapshot (2026-2031)​
- Segment Overview​
- Regional Snapshot​
- Competitive Insights ​
- Market Overview
- Market Dynamics
- Drivers
- Rising prevalence of cancer and chronic diseases
- Growth of precision medicine
- Advancements in nanotechnology
- Expansion of biologics, gene therapies, and RNA therapeutics
- Increasing success of antibody-drug conjugates (ADCs) technologies
- Restraints​
- High development and manufacturing costs
- Complex regulatory requirements
- Safety and toxicity concerns
- Limited accessibility in cost-sensitive markets
- Opportunities​
- Expansion beyond oncology
- Increasing demand for specialized CDMO services
- Emerging market penetration
- Development of next-generation delivery platforms
- Key Market Trends
- Increasing adoption of antibody-drug conjugates (ADCs)
- Growing use of lipid nanoparticle (LNP) delivery systems
- Development of stimulus-responsive drug delivery platforms
- Expansion of exosome-based drug delivery technologies
- Unmet Market Needs​
- Industry Speaks​
- Drivers
- Market Dynamics
- Global Targeted Drug Delivery Market Size & Forecast (2024-2031), By Technology, USD Billion
- Introduction​
- Nanoparticles
- Liposomes
- Antibody-drug Conjugates (ADCs)
- Microspheres and Microcapsules
- Other Technologies
- Global Targeted Drug Delivery Market Size & Forecast (2024-2031), By Route of Administration, USD Billion
- Introduction​
- Injectable
- Oral
- Pulmonary
- Transdermal
- Nasal
- Other Delivery Routes
- Global Targeted Drug Delivery Market Size & Forecast (2024-2031), By Application, USD Billion
- Introduction
- Oncology
- Cardiovascular Diseases (CVDs)
- Neurological Disorders
- Infectious Diseases
- Respiratory Diseases
- Metabolic Disorders
- Other Applications
- Global Targeted Drug Delivery Market Size & Forecast (2024-2031), By End User, USD Billion​
- Introduction​
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutes
- Hospitals and Clinics
- Other End Users
- Global Targeted Drug Delivery Market Size & Forecast (2024-2031), By Region, USD Billion
- Introduction​
- North America Targeted Drug Delivery Market Size & Forecast (2024-2031), By Country, USD Billion​
- US​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)​
- Canada​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)​
- US​
- Europe Targeted Drug Delivery Market Size & Forecast (2024-2031), By Country, USD Billion​
- UK ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- Germany ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- France ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- Italy ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- Spain ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- Rest of Europe ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- UK ​
- Asia Pacific (APAC) Targeted Drug Delivery Market Size & Forecast (2024-2031), By Country, USD Billion​
- China ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- Japan ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- India ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- Rest of Asia Pacific ​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- China ​
- Latin America (LATAM) Targeted Drug Delivery Market Size & Forecast (2024-2031), USD Billion​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- Middle East & Africa (MEA) Targeted Drug Delivery Market Size & Forecast (2024-2031), USD Billion​
- Market Size & Forecast, By Technology (USD Billion)​
- Market Size & Forecast, By Route of Administration (USD Billion)​
- Market Size & Forecast, By Application (USD Billion)​
- Market Size & Forecast, By End User (USD Billion)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2025)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2023-2026)
- New Product Launch & Approval
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- AbbVie Inc.
- AstraZeneca
- Pfizer Inc.
- Baxter
- Boston Scientific Corporation
- Becton, Dickinson and Company (BD)
- Sanofi
- Hoffmann-La Roche Ltd
- Johnson & Johnson
- Arrowhead Pharmaceuticals, Inc.
- Other Prominent Players
Note: *Indicative list
**For listed companies
This report by Medi-Tech Insights provides the size of the global targeted drug delivery market at the regional and country-level from 2024 to 2031. The report further segments the market by technology, route of administration, application, and end user.
- Market Size & Forecast (2024-2031), By Technology, USD Billion
- Nanoparticles
- Liposomes
- Antibody-drug Conjugates (ADCs)
- Microspheres and Microcapsules
- Other Technologies
- Market Size & Forecast (2024-2031), By Route of Administration, USD Billion
- Injectable
- Oral
- Pulmonary
- Transdermal
- Nasal
- Other Delivery Routes
- Market Size & Forecast (2024-2031), By Application, USD Billion
- Oncology
- Cardiovascular Diseases (CVDs)
- Neurological Disorders
- Infectious Diseases
- Respiratory Diseases
- Metabolic Disorders
- Other Applications
- Market Size & Forecast (2024-2031), By End User, USD Billion
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutes
- Hospitals and Clinics
- Other End Users
- Market Size & Forecast (2024-2031), By Region, USD Billion
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
- North America
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, Hospitals and Clinics, and others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Get a sample report for competitive landscape analysis
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
Frequently Asked Questions (FAQs)
Features of the Report
- Comprehensive Market Coverage
- Market Size and Forecast
- Geographic & Segment Deep Dives
- Strategic Insights & Competitive Landscape
- Timely & Updated Data
- Growth Indicators & Future Outlook
- Quick Turnaround on Queries
- Analyst Support
- Report Customization Available
- Reports in PDF & Excel
